GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation
Phase 2
Terminated
- Conditions
- Kidney Transplantation (Status Post)
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7
- Registration Number
- NCT02723786
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle upon Tyne., United Kingdom
A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
Phase 3
Completed
- Conditions
- Herpes Zoster
- Interventions
- Biological: Herpes Zoster Vaccine GSK1437173A
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7541
- Registration Number
- NCT02723773
- Locations
- 🇬🇧
GSK Investigational Site, Liverpool, United Kingdom
A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 185
- Registration Number
- NCT02719743
- Locations
- 🇹🇭
GSK Investigational Site, Chiang Mai, Thailand
This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and 10 Years Later, in Children Who Had Received Havrix at Selected Health Centres of Panama
Not Applicable
Completed
- Conditions
- Hepatitis A Vaccine
- Interventions
- Other: Blood sample collection
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1201
- Registration Number
- NCT02712359
- Locations
- 🇵🇦
GSK Investigational Site, Panamá, Panama
A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT02712047
- Locations
- 🇳🇿
GSK Investigational Site, Newtown, Wellington, New Zealand
Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects
Phase 4
Completed
- Conditions
- Cardiovascular Disease
- Interventions
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT02705807
- Locations
- 🇯🇵
GSK Investigational Site, Okayama, Japan
A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential
Phase 1
Completed
- Conditions
- NeoplasmsDrug Interactions
- Interventions
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 29
- Registration Number
- NCT02706535
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Study Investigating Efficacy of an Occluding Dentifrice for Dentine Hypersensitivity
Not Applicable
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- Other: 0.454% w/w stannous fluoride (1100ppm fluoride)Other: 0.76% sodium monofluorophosphate (1000ppm fluoride)
- First Posted Date
- 2016-03-10
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 409
- Registration Number
- NCT02705716
- Locations
- 🇬🇧
GSK Investigational Site, Wirral, United Kingdom
Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers
Phase 1
Completed
- Conditions
- Embryo Transfer
- Interventions
- Drug: Placebo to match GSK557296
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2018-09-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 31
- Registration Number
- NCT02703181
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
Phase 3
Completed
- Conditions
- Malaria VaccinesMalaria
- Interventions
- Dietary Supplement: Vitamin ABiological: Candidate Plasmodium falciparum malaria vaccineBiological: MR-VacBiological: Stamaril
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 699
- Registration Number
- NCT02699099
- Locations
- 🇬🇭
GSK Investigational Site, Kumasi, Ghana
© Copyright 2025. All Rights Reserved by MedPath